ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

Novel GPCR-targeted small molecule therapeutics designed to impact patients around the world Total of $158 million raised to date SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--ShouTi Inc., a clinical-stage biopharmaceutical company creating life-changin...

Full "IntellAsia: Resources" article